Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 1Diagnosis: Solid Tumor/Phase INCT ID: NCT01714739
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 12-487
To assess the safety and tolerability and preliminary anti-tumor activity of lirilumab/BMS-986015 given in combination with nivolumab/BMS-936558 and to identify dose limiting toxicities (DLTs) and the maximally tolerated dose (MTD) of the combination, in subjects with advanced (metastatic and/or unresectable) solid tumors.
Conducting Institutions: Dana-Farber Cancer Institute, Beth-Israel Deaconess Medical Center, Brigham and Women's Hospital, Massachusetts General Hospital
Overall PI: Frank Stephen Hodi, MD,
Dana-Farber Cancer Institute
Site-responsible Investigators: Daniel Cho, MD,
Beth Israel Deaconess Medical CenterDonald Lawrence, MD,
Massachusetts General Hospital
Contacts: Dana-Farber Cancer Institute:
Andrew Wolanski, 617-632-6623,
email@example.comBeth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100